Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study.

World J Urol · 2022 · PMC9512882 · PMID 36057895

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients receiving CAB showed a trend to a higher rate of CRPC compared to patients not under CAB (21.6 vs 17.5%, 95% CI 14.04–30.81 and 12.91–22.91%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.